 |
 |
 |
 |
 |
 |
 |
 |
Zidovudine (AZT, Retrovir)
Overview
- A Clinical Overview of Zidovudine (AZT, Retrovir) (November 11, 2009)
From AIDSinfo - Prescribing Information for Zidovudine (AZT, Retrovir) Oral Solution (PDF) (November 2009)
From GlaxoSmithKline - Prescribing Information for Zidovudine (AZT, Retrovir) IV Infusion (PDF) (October 2006)
From GlaxoSmithKline - Approval of Generic Zidovudine (September 20, 2005)
[Archived Article]
From U.S. Food and Drug Administration - Drug Interactions: Zidovudine (August 2004)
[Archived Article]
From Project Inform
News
- New Dosing Recommendations Retrovir (Zidovudine) Syrup for HIV-Infected Infants (November 6, 2009)
From U.S. Food and Drug Administration - GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
If you live in the United States, use private health insurance and take Combivir (AZT/3TC), Epzicom (abacavir/3TC, Kivexa), Lexiva (fosamprenavir, Telzir) or another HIV drug made by GlaxoSmithKline, you may have a chance to save a nice chunk of change.
From GlaxoSmithKline - FDA Approves First Generic HIV/AIDS Drug in Capsule Form for United States Market (March 31, 2006)
From U.S. Food and Drug Administration - FDA Approves Four Generic Forms of Zidovudine for U.S. Sales After Retrovir's Patent Expires (September 21, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - GlaxoSmithKline's Patent on Retrovir Expires; Generic Versions of AZT Expected to Be Available Soon (September 20, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Zidovudine Generic Oral Solution Approved in United States (September 20, 2005)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - WHO Removes Cipla's Lamivudine, Zidovudine Generics From Approved Drug List (June 16, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Research
- Literature Citations for Zidovudine (Regularly Updated)
From U.S. National Institutes of Health - Clinical Trials Using Zidovudine (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - Studies Raise Possible Long-Term Concern for Infants Exposed to Retrovir in Womb (April 16, 2007)
From aidsmap.com - HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO - Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - HIV-Positive Mothers Should Continue AZT Prophylaxis After Childbirth, Study Says (October 3, 2004)
[Archived Article]
A study finds a brief jump in breast milk viral load following AZT cessation.
From aidsmap.com - Improvement in Lipoatrophy Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study (January 15, 2004)
[Archived Article]
When people who had developed lipoatrohpy while taking d4T (stavudine, Zerit) switched to abacavir (Ziagen) or AZT (zidovudine, Retrovir), their condition improved.
In Clinical Infectious Diseases - Mother-to-Child Transmission: How Will AZT and Nevirapine Use for MTCT Affect Future Treatment? (Winter 2003/2004)
[Archived Article]
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - Abstract 16: Long-Term Changes in Lipodystrophy After Switching From Thymidine Nucleoside Analogs to Abacavir (October 2003)
[Archived Article]
5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, July 8-11, 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care - No PK Interaction Seen Between FTC and AZT or Tenofovir (September 16, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Abacavir Not Inferior to AZT in Treatment-Naive Patients (September 14, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Nevirapine Reduced Mother-to-Child Transmission Better Than AZT -- At 70 Times Less Cost (September 12, 2003)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News - Substituting AZT or Abacavir for d4T in Patients With Lipoatrophy (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Improvements in Body Fat and Mitochondrial DNA Levels Are Accompanied by Decreased Adipose Tissue Cell Apoptosis After Replacement of Stavudine Therapy With Either Abacavir or Zidovudine (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Intracellular Metabolism of AZT Leads to the Production of Significant Levels of d4T Triphosphate in HIV Infected Patients (November 19, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Effect of Stavudine, Zidovudine and HIV Protease Inhibitor Therapy on Subcutaneous Leg Fat Wasting in HIV-Infected Males -- A Longitudinal Study (September 25, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Lack of Recurrence of Symptomatic and Asymptomatic Hyperlactatemia When Stavudine Is Replaced by Either Abacavir or Zidovudine: 48-Week Data (September 24, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO - Nevirapine During Labor and in the Neonate Significantly Improves Zidovudine Prophylaxis for the Prevention of Perinatal HIV Transmission: Results of PHPT-2 First Interim Analysis (July 12, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO - Pharmacodynamic Effects of Zidovudine 600 mg Once Daily Versus Zidovudine 300 mg Twice Daily in Therapy-Naive HIV-Infected Patients (COD20002) (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO - Zidovudine and Lamivudine Seminal Plasma: Blood Plasma Concentration Ratios Do Not Predict Total SP Exposure (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO - Durability and Tolerability of the Triple NRTI Regimen Abacavir/Zidovudine/Lamivudine Based on Therapy Changes in Antiretroviral Therapy-Naive Patients in the Frankfurt HIV Cohort (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO - Short-Course AZT Lowers MTCT Rates Among Some Breast-Feeding Mothers (Summer/Autumn 2002)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - New Zidovudine-Resistant HIV Found in Treatment-Naive Patients (December 2001)
[Archived Article]
In HEPP News, from Brown Medical School - Phosphorylation of Zidovudine, Stavudine, and Abacavir in Peripheral Blood Mononuclear Cells in Treatment-Naive and Treatment-Experienced Patients (February 5, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Clinical Management
Clinical Management
  |
The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.